Search

Your search keyword '"McLaurin, Kimmie"' showing total 186 results
Start Over Author "McLaurin, Kimmie"
186 results on '"McLaurin, Kimmie"'

6. #512 Real-World utilisation and clinical outcomes of patients with BRCA-mutated advanced ovarian cancer treated with olaparib in the first-line maintenance setting: 2-year clinical outcomes of the pan-European OVAL-1 study

Author

Lorusso, Domenica, primary, Garbay, Delphine, additional, Roger Asselain, Bernard Jean, additional, Miller, Rowan, additional, Raspagliesi, Francesco, additional, Zamagni, Claudio, additional, Leary, Alexandra, additional, Bellier, Charlotte, additional, Glasspool, Ros, additional, Jayson, Gordon, additional, Grevat, Emmanuelle, additional, Kertous, Mehdi, additional, Sabatucci, Ilaria, additional, Padrone, Claudia, additional, Jayia, Parveen, additional, Hada, Manila, additional, Mclaurin, Kimmie, additional, and Gourley, Charlie, additional

Published
2023
Full Text
View/download PDF

22. Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US

Author

McLaurin,Kimmie K, Wade,Sally W, Kong,Amanda M, Diakun,David, Olajide,Ifedapo R, and Germano,Jane

Subjects
health care costs, claims database, birth hospitalization, Pediatric Health, Medicine and Therapeutics, health care economics and organizations, Original Research, premature
Abstract

Kimmie K McLaurin,1 Sally W Wade,2 Amanda M Kong,3 David Diakun,3 Ifedapo R Olajide,1 Jane Germano4 1US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA; 2Wade Outcomes Research and Consulting, Salt Lake City, UT, USA; 3IBM Watson Health, Cambridge, MA, USA; 4Department of Pediatrics, MedStar Georgetown University Hospital, Washington, DC, USA Purpose: This study examined health care utilization and costs during the first year of life for preterm and full-term infants in the US. Subjects and methods: Preterm (75%) of preterm infants were admitted to the neonatal intensive care unit during their birth hospitalization. Generally, mean length of stay and costs for birth hospitalizations increased with decreasing GA. The average cost of a birth hospitalization was US $62,931 (SD $134,347) for commercially insured preterm infants and $43,858 (SD $115,412) for Medicaid-insured preterm infants compared to $2,401 (SD $7,399) and $1,894 (SD $5,444) for commercially insured and Medicaid-insured full-term infants, respectively. Post-neonatal hospitalization rates increased as GA decreased (in full-termto

Published
2019

38. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis

Author

Anderson, Evan J., additional, DeVincenzo, John P., additional, Simões, Eric A. F., additional, Krilov, Leonard R., additional, Forbes, Michael L., additional, Pannaraj, Pia S., additional, Espinosa, Claudia M., additional, Welliver, Robert C., additional, Wolkoff, Leslie I., additional, Yogev, Ram, additional, Checchia, Paul A., additional, Domachowske, Joseph B., additional, Halasa, Natasha, additional, McBride, Scott J., additional, Kumar, Veena R., additional, McLaurin, Kimmie K., additional, Rizzo, Christopher P., additional, and Ambrose, Christopher S., additional

Published
2019
Full Text
View/download PDF

39. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCAMutation Status

Author

Collins, Jenna M., Nordstrom, Beth L., McLaurin, Kimmie K., Dalvi, Tapashi B., McCutcheon, Susan C., Bennett, James C., Murphy, Brian R., Singhal, Puneet K., McCrea, Charles, Shinde, Reshma, and Briceno, Josefa M.

Abstract

Introduction: Limited data exist on real-world treatment patterns and the effectiveness of cyclin-dependent kinase (CDK) 4/6 inhibitors in germline BRCA(gBRCA)-mutated breast cancer. Methods: Adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) treated with CDK4/6 inhibitor therapy between 2013 and 2018 were retrospectively selected from the Flatiron Health database. Patients with known gBRCAstatus were classified as mutated (gBRCAm) or wild type (gBRCAwt). Time-to-first subsequent therapy or death (TFST) and overall survival (OS) were calculated from the earliest line of therapy with a CDK4/6 inhibitor. Results: Of 2968 patients with HR+/HER2− mBC receiving a CDK4/6 inhibitor, 859 (28.9%) had known gBRCAstatus, of whom 9.9% were gBRCAm and 90.1% gBRCAwt. Median (95% confidence interval [CI]) TFST was 10 (7–11) months in the gBRCAm group, 10 (9–11) months in the gBRCAwt group, and 11 (10–12) months in the combined gBRCAwt and unknown gBRCAgroup; median (95% CI) OS was 26 (21–not estimated), 37 (31–51), and 33 (31–35) months, respectively. Cox models indicated the gBRCAm group had shorter TFST (stratified hazard ratio [sHR] 1.24; 95% CI 0.96–1.59) and OS (sHR 1.50; 95% CI 1.06–2.14) than the gBRCAwt group. The gBRCAm group had shorter TFST (sHR 1.38; 95% CI 1.08–1.75) and OS (sHR 1.22; 95% CI 0.88–1.71) than the combined group. Conclusion: The results of this real-world study suggest that treatment outcomes with CDK4/6 inhibitors may be worse in patients with gBRCAm mBC than in their counterparts with gBRCAwt and unknown gBRCAstatus, suggesting potential differences in tumor biology. This result highlights the unmet need in patients with gBRCAm requiring optimized treatment selection and sequencing. Future exploration in larger samples of patients who have had biomarker testing is warranted.

Published
2021
Full Text
View/download PDF

40. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Author

Anderson, Evan J., DeVincenzo, John P., Simões, Eric A. F., Krilov, Leonard R., Forbes, Michael L., Pannaraj, Pia S., Espinosa, Claudia M., Welliver, Robert C., Wolkoff, Leslie I., Yogev, Ram, Checchia, Paul A., Domachowske, Joseph B., Halasa, Natasha, McBride, Scott J., Kumar, Veena R., McLaurin, Kimmie K., Rizzo, Christopher P., and Ambrose, Christopher S.

Subjects
AGE distribution, ARTIFICIAL respiration, GESTATIONAL age, HOSPITAL care, IMMUNIZATION, INTENSIVE care units, MEDICAL care use, PEDIATRICS, COMMUNITY-acquired infections, PALIVIZUMAB, RESPIRATORY syncytial virus infections, CHILDREN
Abstract

Objective  The SENTINEL1 observational study characterized confirmed respiratory syncytial virus hospitalizations (RSVH) among U.S. preterm infants born at 29 to 35 weeks' gestational age (wGA) not receiving respiratory syncytial virus (RSV) immunoprophylaxis (IP) during the 2014 to 2015 and 2015 to 2016 RSV seasons. Study Design  All laboratory-confirmed RSVH at participating sites during the 2014 to 2015 and 2015 to 2016 RSV seasons (October 1–April 30) lasting ≥24 hours among preterm infants 29 to 35 wGA and aged <12 months who did not receive RSV IP within 35 days before onset of symptoms were identified and characterized. Results  Results were similar across the two seasons. Among infants with community-acquired RSVH (N  = 1,378), 45% were admitted to the intensive care unit (ICU) and 19% required invasive mechanical ventilation (IMV). There were two deaths. Infants aged <6 months accounted for 78% of RSVH observed, 84% of ICU admissions, and 91% requiring IMV. Among infants who were discharged from their birth hospitalization during the RSV season, 82% of RSVH occurred within 60 days of birth hospitalization discharge. Conclusion  Among U.S. preterm infants 29 to 35 wGA not receiving RSV IP, RSVH are often severe with almost one-half requiring ICU admission and about one in five needing IMV. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016

Author

Goldstein, Mitchell, additional, Krilov, Leonard, additional, Fergie, Jaime, additional, McLaurin, Kimmie, additional, Wade, Sally, additional, Diakun, David, additional, Lenhart, Gregory, additional, Bloomfield, Adam, additional, and Kong, Amanda, additional

Published
2018
Full Text
View/download PDF

49. Respiratory Syncytial Virus (RSV) Hospitalizations of US Preterm Infants Born at 29–35 Weeks Gestational Age: Proportions by Chronologic Age and Birth Month

Author

Anderson, Evan J, primary, Simões, Eric A, additional, Forbes, Michael L, additional, Checchia, Paul A, additional, Domachowske, Joseph B, additional, Krilov, Leonard R, additional, Halasa, Natasha B, additional, Devincenzo, John P, additional, Rizzo, Christopher, additional, McLaurin, Kimmie K, additional, and Ambrose, Christopher S, additional

Published
2017
Full Text
View/download PDF

50. The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists

Author

Wong, Pierre C., primary, Parimi, Prabhu S., additional, Domachowske, Joseph B., additional, Friedman, Deborah M., additional, Marcus, Michael G., additional, Garcia, Daniel F., additional, La Via, William V., additional, Syed, Iqra A., additional, Szabo, Shelagh M., additional, McLaurin, Kimmie K., additional, and Kumar, Veena R., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results